BioCentury
ARTICLE | Company News

Corimmun, J&J deal

July 2, 2012 7:00 AM UTC

Johnson & Johnson's Janssen-Cilag GmbH unit acquired CorImmun for an upfront payment and milestones. CorImmun's COR-1, a cyclic peptide targeting autoantibodies directed against adrenergic receptor ...